drugset
drugset / Trial / NCT07432087

Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT07432087 ↗

Phase 3 Not yet recruiting 246 enrolled Yue He, MD
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, randomized, controlled, multicenter, non-inferiority clinical study designed to evaluate the efficacy and safety of camrelizumab combined with EGFR monoclonal antibody or chemotherapy as perioperative treatment of locally advanced head and neck squamous cell carcinoma.

Timeline

Start
2026-02-01
Primary completion
2030-12-31
Completion
2033-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carboplatin Small molecule 4 unknown Intravenous
Subject Cetuximab Monoclonal antibody 250 mg/m2 Intravenous
Comparator Paclitaxel Small molecule 125 mg/m2 Intravenous
Background Camrelizumab Monoclonal antibody 200 mg Intravenous

Indications

head and neck squamous cell carcinoma